

# Curriculum Vitae

---

Marco Roffi, MD, FESC

Application for the position of Vice-President

Photo



## Personal Information:

**Place and Date of Birth:** Lugano, Switzerland, 09.03.1966

**Nationality:** Swiss

## Current Position and Professional Address

Full Professor, University of Geneva, Switzerland

Director, Interventional Cardiology Unit (from 2008) (Chair of Cardiology Prof. Francois Mach)

University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland

Previous position (2002-2008) Staff and then Co-Director, Andreas Grüntzig Cardiac Catheterisation Laboratory, University Hospital, Zurich, Switzerland (Chair of Cardiology Prof. Thomas F. Lüscher)

## Education and Postgraduate Training

School of Medicine, University of Bern, Switzerland

Internal medicine training (Lugano and Zurich, Switzerland), title of Swiss Specialist in Internal Medicine

General Cardiology and Interventional Cardiology Fellowship, Bern, Switzerland (Chair Prof. Bernhard Meier), title of Swiss Specialist in Cardiology

2-year Advanced Interventional Cardiology Fellowship in coronary, peripheral, and carotid interventions, Cleveland Clinic, Cleveland, Ohio, USA (Chair Prof. Eric Topol)

## European Society of Cardiology Activities

### European Association of Percutaneous Cardiovascular Intervention (EAPCI)

- Member since 2008
- Co-chair (2009-2011) and Chair (2012-2014) of the EAPCI Scientific Program Committee
- Member of the Scientific Program Committee of EuroPCR (2009-2019)
- Member of the Fellowship Grant Committee (2022-2024)

### ESC Working Group on Aorta and Peripheral Vascular Diseases

- Member since 2005
- Nucleus member (2005-2010)

## European Society of Cardiology (ESC)

- Fellow (FESC) (since 2005)
- Member of the Congress Programme Committee (CPC) (2011-2020 and 2022-2024)
  - o Chairperson of the 2019 ESC congress in Paris – with 33'510 registered persons from 151 countries to date the most well attended ESC congress edition
  - o Chairperson of the 2020 ESC congress „The Digital Experience“ – with 125'300 registered persons from 213 countries to date arguably the most well attended virtual congress in cardiovascular medicine worldwide
- Member of the Committee for Practice Guidelines (2014-2020)
  - o Member of ESC guideline Task Forces on peripheral artery disease (2011 and 2017), non-cardiac surgery (2014), aortic diseases (2014), STEMI (2017), DAPT (2017), diabetes (2019), and COVID-19 (2020-2021)
  - o Chairperson of the ESC 2015 NSTE-ACS guideline task force
  - o Appointed reviewer of 19 ESC guidelines/consensus documents
- Member of the Committee for Global Scientific Activities (2014-2022)
  - o ESC Ambassador for the Middle East and India (2018-2022)
- Nucleus member of the ESC Cardiovascular Roundtable (CRT) (2020-2022)
- ESC Councillor and member of the ESC Board (2024-2026)
  - o Chair of the Membership Committee
  - o Chair of the Declaration of Interest (DOI) Committee
- Member of the Global affairs Task Force (since 2024)
  - o ESC regional representative for India, China and the Middle East
- Initiator, together with Thomas Lüscher (ESC President) and Jean-Francois Riffaud (ESC CEO) and with the support of Franz Weidinger, ESC Past President and Chair of the ESC Global Affairs Task Force, of the ESC Action in Development (ESC-AID), a new ESC initiative for the prevention, diagnosis and treatment of cardiovascular diseases in healthcare deprived countries

## **Participation in Other International Scientific Committees**

None

## **Editorial Boards**

- Member of the Editorial Board of European Heart Journal (since 2012)
- Co-Editor of the European Heart Journal (since 2022)
- International Associate Editor of Cardiology Discovery, the journal of the Chinese Society of Cardiology (since its inception in 2020)

## **Leadership and Management Experience**

- In my institution: I'm in charge of the interventional cardiology unit of a University Hospital
- In the Swiss Society of Cardiology: I was president of the Swiss Working Group Interventional Cardiology
- In the ESC: I chaired the ESC congress for two editions, a ESC guideline Task Force, 2 ESC Board Committees, and the EAPCI Scientific Program Committee

## Fellowships and Honours

- Scholarship of the Swiss Research Science Foundation
- F. Merlin Bumpus Junior Investigator Award, Cleveland Clinic, Cleveland, Ohio, USA.
- Winner of the Research Prize of the Swiss Heart Foundation.
- Fellow of the European Society of Cardiology (FESC)
- Fellow of the American College of Cardiology (FACC)

## Honorary Memberships

None

## Top 10 Most Relevant Publications

1. Schnyder G, **Roffi M**, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001;345:1593-600.
2. **Roffi M**, Chew DP, Mukherjee M, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndromes. *Circulation* 2001;104:2767-71.
3. **Roffi M**, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes: Gradient of benefit related to the revascularization strategy. *Eur Heart J* 2002; 23:1441-8.
4. **Roffi M**, Moliterno DJ, Meier B, et al. The impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: TARGET 1-year follow up. *Circulation* 2002, 105:2730-6.
5. **Roffi M**; Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials. *Circulation* 2002, 106:3063-7.
6. **Roffi M**, Wenaweser P, Windecker S, et al. Early exercise after coronary stenting is safe. *J Am Coll Cardiol* 2003;42:1569-73.
7. **Roffi M**, Patrono C, Collet JP, et al. .2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016;37:267-315.
8. **Roffi M**, Radovanovic D, Iglesias JF, et al. Multisite vascular disease in acute coronary syndromes: increased in-hospital mortality and no improvement over time. *Eur Heart J Acute Cardiovasc Care* 2020;9:748-57.
9. Iglesias JF, **Roffi M**, Losdat S, Muller O, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. *Lancet* 2023;402:1979-90.
10. **Roffi M**, Landi A, Heg D, et al. Abbreviated or Standard Antiplatelet Therapy After Percutaneous Coronary Intervention In Patients with Diabetes and High Bleeding Risk: a prespecified analysis from the MASTER DAPT trial. *JACC Cardiovasc Interv* 2024;17:2664-77.

## Major Research Interest

- Acute coronary syndromes, antiplatelet therapy, coronary artery disease in diabetes, drug-eluting stents, percutaneous treatment of peripheral and carotid disease.
- Co-author of over 400 publications listed in PubMed, H-Index of 67 (Clarivate Web of Science, accessed December 3, 2025).